KR102291860B1 - Hif 하이드록실라제 억제자의 약학적 제형 - Google Patents

Hif 하이드록실라제 억제자의 약학적 제형 Download PDF

Info

Publication number
KR102291860B1
KR102291860B1 KR1020157034392A KR20157034392A KR102291860B1 KR 102291860 B1 KR102291860 B1 KR 102291860B1 KR 1020157034392 A KR1020157034392 A KR 1020157034392A KR 20157034392 A KR20157034392 A KR 20157034392A KR 102291860 B1 KR102291860 B1 KR 102291860B1
Authority
KR
South Korea
Prior art keywords
capsule
weight
iron oxide
photostabilizer
titanium dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157034392A
Other languages
English (en)
Korean (ko)
Other versions
KR20160018514A (ko
Inventor
데이비드 콘카
리 알렌 플리핀
스코트 데이비드 리
클라우디아 윗쉬
리 로버트 라이트
Original Assignee
피브로겐, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102291860(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피브로겐, 인크. filed Critical 피브로겐, 인크.
Priority to KR1020217025795A priority Critical patent/KR20210104173A/ko
Publication of KR20160018514A publication Critical patent/KR20160018514A/ko
Application granted granted Critical
Publication of KR102291860B1 publication Critical patent/KR102291860B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157034392A 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형 Active KR102291860B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217025795A KR20210104173A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
US61/831,909 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217025795A Division KR20210104173A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Publications (2)

Publication Number Publication Date
KR20160018514A KR20160018514A (ko) 2016-02-17
KR102291860B1 true KR102291860B1 (ko) 2021-08-20

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227041268A Ceased KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020217025795A Ceased KR20210104173A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020157034392A Active KR102291860B1 (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020227041268A Ceased KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020217025795A Ceased KR20210104173A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Country Status (24)

Country Link
US (3) US20160120859A1 (enExample)
EP (2) EP3708154A1 (enExample)
JP (4) JP6604941B2 (enExample)
KR (3) KR20220164069A (enExample)
CN (5) CN105377242A (enExample)
AU (1) AU2014274890B2 (enExample)
CA (1) CA2914049C (enExample)
CY (1) CY1122951T1 (enExample)
DK (1) DK3003284T3 (enExample)
ES (1) ES2786924T3 (enExample)
HR (1) HRP20200615T1 (enExample)
HU (1) HUE049623T2 (enExample)
IL (3) IL296484B2 (enExample)
LT (1) LT3003284T (enExample)
ME (1) ME03777B (enExample)
MX (3) MX2015016536A (enExample)
PL (1) PL3003284T3 (enExample)
PT (1) PT3003284T (enExample)
RS (1) RS60464B1 (enExample)
SG (1) SG11201509764RA (enExample)
SI (1) SI3003284T1 (enExample)
SM (1) SMT202000190T1 (enExample)
WO (1) WO2014197660A1 (enExample)
ZA (1) ZA201508712B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CN109369524A (zh) 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CA3074529C (en) 2017-09-04 2022-07-05 Sandoz Ag Co-crystal of roxadustat with l-proline and uses thereof
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087237A1 (ja) 2004-03-16 2005-09-22 Asahi Kasei Pharma Corporation ファスジル含有製剤及びその安定性を改善する方法
JP2006527200A (ja) 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
US20120149712A1 (en) 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2507002C (en) 2002-12-16 2012-09-18 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
EA016713B1 (ru) 2005-10-31 2012-07-30 Кова Ко., Лтд. Таблетка с насечкой, обладающая превосходной фотостабильностью
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
DK2044028T3 (da) 2006-01-27 2012-08-20 Fibrogen Inc Cyanoisoquinolinforbindelser til stabilisering af den hypoxiinducerende faktor (HIF)
ES2342727T3 (es) * 2006-02-09 2010-07-13 Teva Pharmaceutical Industries Ltd. Formulaciones farmaceuticas estables de montelukast sodico.
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
CN101896210A (zh) 2007-10-12 2010-11-24 阿斯利康(瑞典)有限公司 含有甘露醇和/或微晶纤维素的齐泊腾坦组合物
AU2008319229A1 (en) 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009075824A1 (en) 2007-12-06 2009-06-18 Fibrogen, Inc. Methods for increasing endothelial progentior cells
WO2009075826A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
EP2382971A4 (en) 2009-01-29 2014-01-08 Dainippon Sumitomo Pharma Co ORAL DISINTEGRATING TABLE COMPRISING AN INDOOR CORE
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
WO2013013609A1 (en) 2011-07-22 2013-01-31 Zhejiang Beta Pharma Incorporation Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
CN109369524A (zh) 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149712A1 (en) 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
JP2006527200A (ja) 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
WO2005087237A1 (ja) 2004-03-16 2005-09-22 Asahi Kasei Pharma Corporation ファスジル含有製剤及びその安定性を改善する方法
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical Capsules, Pharmaceutical Press, GB pp 64-66 (2004. 01. 01.)

Also Published As

Publication number Publication date
JP2023068197A (ja) 2023-05-16
IL242759B1 (en) 2023-01-01
IL242759A (enExample) 2015-12-31
US20160120859A1 (en) 2016-05-05
NZ714554A (en) 2021-06-25
CN110448537A (zh) 2019-11-15
EP3003284B1 (en) 2020-02-12
CA2914049C (en) 2021-10-12
KR20160018514A (ko) 2016-02-17
JP2016523846A (ja) 2016-08-12
AU2014274890A1 (en) 2015-12-17
JP6861758B2 (ja) 2021-04-21
SG11201509764RA (en) 2015-12-30
JP2019137703A (ja) 2019-08-22
WO2014197660A1 (en) 2014-12-11
IL242759B2 (en) 2023-05-01
CN111728950A (zh) 2020-10-02
IL296484A (en) 2022-11-01
US20220054474A1 (en) 2022-02-24
SI3003284T1 (sl) 2020-08-31
JP2021100971A (ja) 2021-07-08
IL298998A (en) 2023-02-01
RU2681304C2 (ru) 2019-03-06
MX2020003096A (es) 2020-08-17
CY1122951T1 (el) 2021-10-29
RU2015151056A (ru) 2017-07-14
HUE049623T2 (hu) 2020-09-28
KR20210104173A (ko) 2021-08-24
EP3708154A1 (en) 2020-09-16
IL296484B2 (en) 2025-03-01
ES2786924T3 (es) 2020-10-14
HK1222550A1 (en) 2017-07-07
RU2015151056A3 (enExample) 2018-05-03
BR112015029693A2 (pt) 2017-07-25
MX2015016536A (es) 2016-08-11
PT3003284T (pt) 2020-08-10
CN111728951A (zh) 2020-10-02
RS60464B1 (sr) 2020-07-31
AU2014274890B2 (en) 2019-10-03
BR112015029693A8 (pt) 2019-12-24
PL3003284T3 (pl) 2020-08-10
KR20220164069A (ko) 2022-12-12
IL298998B2 (en) 2024-07-01
HRP20200615T1 (hr) 2020-07-10
IL298998B1 (en) 2024-03-01
JP6604941B2 (ja) 2019-11-13
EP3003284A1 (en) 2016-04-13
ME03777B (me) 2021-04-20
DK3003284T3 (da) 2020-03-30
CA2914049A1 (en) 2014-12-11
IL296484B1 (en) 2024-11-01
US10765672B2 (en) 2020-09-08
ZA201508712B (en) 2020-07-29
LT3003284T (lt) 2020-04-27
NZ754196A (en) 2021-06-25
MX2022011225A (es) 2022-10-07
CN105377242A (zh) 2016-03-02
SMT202000190T1 (it) 2020-05-08
CN111728952A (zh) 2020-10-02
US20190008846A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
KR102291860B1 (ko) Hif 하이드록실라제 억제자의 약학적 제형
US20200297756A1 (en) Pharmaceutical formulations of nitrite and uses thereof
CN118806764A (zh) 缓释制剂及其使用方法
HK40032448A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
HK1222550B (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
NZ754196B2 (en) Pharmaceutical formulations of a HIF hydroxylase inhibitor
BR112015029693B1 (pt) Comprimido e cápsula compreendendo ácido [(4-hidróxi-1-metil-7-fenóxi-isoquinolina-3-carbonil)-amino]-acético
NZ714554B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190326

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200922

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210514

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210813

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210817

End annual number: 3

Start annual number: 1

PG1601 Publication of registration